Q-omics provides the consensus-scored CD177 profile across patient tissues and cancer cell-line models. CD177 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD177 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CD177 protein abundance shows 17,479 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, COAD, and LUAD as cancer lineages where CD177 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD177 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD177 survival associations across molecular data types. CD177 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD177 RNA expression–survival associations across cancer types. High CD177 expression shows favorable associations in HNSC, CESC, PRAD, KIRC, LUAD and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for CD177 RNA expression.
This table summarizes CD177 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CD177. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD177 shows lower tumor expression in COAD and READ and higher tumor expression in THCA, BRCA, LUSC and STAD. The COAD box plot shows higher CD177 RNA expression in normal versus tumor tissue (log2 FC = −6.694, t-test p < 0.001).
This table shows molecular features associated with CD177 in patient tissues and cancer cell lines. In patient samples, CD177 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CD177 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
